Nurix Advances Leukemia Treatment With First Patient in Combination Therapy Study

Nurix Therapeutics has enrolled its first patient in a Phase 1b/2 trial combining bexobrutideg, an investigational BTK degrader, with venetoclax for treating chronic lymphocytic leukemia. The study will evaluate the safety and efficacy of the combination in relapsed or refractory patients, with potential expansion to first-line treatment and evaluation of additional antibody partners from Roche's portfolio. Trial data is expected to guide future development strategies across multiple patient populations and potentially other B-cell malignancies.

Bexobrutideg represents a novel approach to leukemia treatment through targeted protein degradation, a mechanism designed to destroy cancer-driving proteins rather than simply inhibit them. The drug is being jointly developed by Nurix and Roche, positioning this trial within a broader clinical program that spans multiple patient populations and treatment settings. This Phase 1b/2 study will systematically assess how the degrader works alongside venetoclax, an established therapy that functions through a different biological pathway, potentially enabling deeper remissions.

The trial design reflects evolving treatment strategies in chronic lymphocytic leukemia, where combination approaches aim to achieve sustained responses with fixed-duration therapy rather than continuous treatment. Future expansion phases could incorporate additional Roche-developed antibodies targeting the CD20 protein, which plays a central role in B-cell malignancies. Success in this indication could inform development across other blood cancers, expanding the potential patient population benefiting from this drug class.